Laine. Good quarter Thanks, everyone, call. XXXX afternoon, second our welcome and to earnings
to the million our Derrick prior me a record U.S. delivered In strategy, sales, period in XX% year while new sales. performance of million the Financial Sung, continuing market Here high growth we and representing geographic initiatives. second driven expansion over by same worldwide commercial Chief $XX $XX.X another in with advance of Officer. executed of the we our QX, our on is quarter, In
Given the to $XX in prior year we full in XXXX second million revenue million, our momentum $XX be million. are million the our to guidance $XX range positive of saw updating from the to of quarter, guidance up $XX we
on progress Zephyr facilitate treatment of centers our U.S. awareness practices best of the one, be three, physicians patients. sharing hospitals Zephyr the have Throughout train focused existing COPD that performing and we our optimize make two, to local programs; centers; benefits quarter, strategy second high to to Valve to commercial build among their and the continued to: potential Valve of
our their in areas to year, accounts Valve many procedure investment. seeing Zephyr programs additional coordinators and allow for of of invest Increasingly, of the we hospitals are other strategic half chose first In view program capacity. resources this as to
cancer and of approach care to implementing treat and lung for up increasingly to severe protocols are hospitals with their working Valve screening emphysema, suspected Zephyr addition, patients standard identify In routine similar patients.
This its workup growth in changed other being emphysema otherwise protocol example, is by For recently referred a are a has substantial physicians routine of for at every with and for evaluations to the to the lung patients suspicion function endobronchial evaluated might that severe hyperinflated test ensure led been in in hyperinflation hospital this to valves. have patients missed account identified that system. at Midwest
early pleased I’m are and starting to we that report to are that increased productivity. translating see these efforts evidence into
number those been active, the based past a Zephyr on measure reminder, X established Valve performing by hospitals, given procedures placed our current and Zephyr revenue in the we cases are generating conducted order As Valve account quarter. of a quarter that productivity have the a in treating pver quarters have average which
average X U.S. and quarter average account has Over up back the center. account year, the cases trended in U.S. cases and per in account, of XXXX, X.X productivity X productivity past second to ranged per between the
seasonal some this to to productivity continue will we variability While trends from over metric on average, in drive account expect quarter-to-quarter, time, higher. move
U.S. second XX%. was in Meanwhile, XXXX account activity quarter the of
activity the generating treating of accounts quarter. revenue as that in given account a place As a order a define percentage reminder, we
We treating range continue denominator activity in mid-XXs centers. grow of account to to remain our we expect the as
our second expectation new which bringing is adding XX communicated number toward new total of our having new previously of to U.S. end centers U.S. centers XX this quarter end year. of the the high centers, expanded year XX opened now our approximately the commercial to centers XXX. of XXXX, further also We expect to in footprint, of XX in We the
through expansion in to later in From this year achieved we post-market anticipate approval Valve of our perspective, Once study. in Japan Japan year. reimbursement we and initiate reimbursement established, Zephyr a geographic sales continue last Japan regulatory a establishment is the will of
As grow from option. XXX,XXX take stand who estimate Japan treatment anticipate patients awareness time We will our to a has new we to benefit this approximately it of treatment. reminder, though,
AeriSeal expand which the emphysema In track with our our patients collateral solution on Valve addressable clinical Zephyr for will remain timeline, development we with our market expect we ventilation. of program, severe
presented trial X data expect in be CONVERT announce happy that our final quarter second completed and to to we I’m year. during the enrollment next
X, form the next CONVERT basis of we trial, our from support discussions in AeriSeal this, preparing will X with We results and clinical Again, late multinational of are the our FDA. CONVERT PMA to submission. stage in are also launch
our In is confident the business. and go-forward execution growth XXXX, in our of our am long-term for expectations commercial our on I trajectory track. summary, strategy,
over to the I’ll With more our provide turn that, results. to detailed a call quarter Derrick now review of second